HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy.
HBV DNA
cirrhosis
quantitative HBsAg
quantitative HDV RNA
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
17 05 2023
17 05 2023
Historique:
received:
13
03
2023
revised:
12
05
2023
accepted:
15
05
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Identification of outcome predictors is one of the unmet needs in chronic HDV infection. Until recently, no reliable quantitative assays for HDV RNA were available. To evaluate the impact of baseline viremia on natural history of HDV infection in a cohort of patients whose serum samples were stored at their first visit 15 years ago. Quantitative HBsAg, HBeAg, HBeAb, HBV DNA, HDV RNA, genotypes, and liver disease severity were assessed at baseline. Patients who were no longer on active follow-up were recalled and re-evaluated in August 2022. The majority of patients were male (64.9%); the median age was 50.1 years; and all patients were Italian, with only three born in Romania. All were HBeAg negative with HBV genotype D infection. Patients were subdivided three groups: 23 were in active follow-up (Group 1), 21 were recalled due to no longer being in follow-up (Group 2), and 11 died (Group 3). Liver cirrhosis was diagnosed in 28 subjects at the first visit; 39.3% of diagnosed patients were in Group 3, 32.1% were in Group 1 and 28.6% were in Group 2 ( HDV chronic infection is a heterogeneous disease. It may not only progress but also improve over time in patients, who eventually become HDV RNA-undetectable. HDV RNA levels may help identify the subgroup of patients with less progressive liver disease.
Sections du résumé
BACKGROUND
Identification of outcome predictors is one of the unmet needs in chronic HDV infection. Until recently, no reliable quantitative assays for HDV RNA were available.
AIMS
To evaluate the impact of baseline viremia on natural history of HDV infection in a cohort of patients whose serum samples were stored at their first visit 15 years ago.
METHODS
Quantitative HBsAg, HBeAg, HBeAb, HBV DNA, HDV RNA, genotypes, and liver disease severity were assessed at baseline. Patients who were no longer on active follow-up were recalled and re-evaluated in August 2022.
RESULTS
The majority of patients were male (64.9%); the median age was 50.1 years; and all patients were Italian, with only three born in Romania. All were HBeAg negative with HBV genotype D infection. Patients were subdivided three groups: 23 were in active follow-up (Group 1), 21 were recalled due to no longer being in follow-up (Group 2), and 11 died (Group 3). Liver cirrhosis was diagnosed in 28 subjects at the first visit; 39.3% of diagnosed patients were in Group 3, 32.1% were in Group 1 and 28.6% were in Group 2 (
CONCLUSIONS
HDV chronic infection is a heterogeneous disease. It may not only progress but also improve over time in patients, who eventually become HDV RNA-undetectable. HDV RNA levels may help identify the subgroup of patients with less progressive liver disease.
Identifiants
pubmed: 37408247
pii: cells12101413
doi: 10.3390/cells12101413
pmc: PMC10217045
pii:
doi:
Substances chimiques
Hepatitis B e Antigens
0
DNA, Viral
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Hepatology. 2020 Oct;72(4):1177-1190
pubmed: 32145073
Gastroenterology. 2004 Jun;126(7):1740-9
pubmed: 15188169
Emerg Infect Dis. 2006 Sep;12(9):1447-50
pubmed: 17073101
Hepatology. 2016 Nov;64(5):1483-1494
pubmed: 27530084
J Hepatol. 2020 Sep;73(3):523-532
pubmed: 32335166
Hepatology. 2014 Jul;60(1):87-97
pubmed: 24585488
Liver Int. 2020 Feb;40 Suppl 1:48-53
pubmed: 32077599
J Viral Hepat. 2018 Aug;25(8):911-919
pubmed: 29577518
Medicine (Baltimore). 2021 Jul 16;100(28):e26571
pubmed: 34260535
PLoS One. 2014 Mar 21;9(3):e92062
pubmed: 24658127
J Viral Hepat. 2022 Jan;29(1):78-86
pubmed: 34585819
Gastroenterology. 1995 Mar;108(3):796-802
pubmed: 7875481
J Viral Hepat. 2010 Nov;17(11):749-56
pubmed: 20723036
Am J Gastroenterol. 2005 Jul;100(7):1626-7
pubmed: 15985000
Liver Int. 2018 May;38(5):842-850
pubmed: 28963781
Gastroenterology. 1999 Jul;117(1):161-6
pubmed: 10381923
Semin Liver Dis. 2012 Aug;32(3):245-55
pubmed: 22932973
Antiviral Res. 2021 Jan;185:104995
pubmed: 33321155
J Clin Virol. 2021 Sep;142:104932
pubmed: 34333392
Transplantation. 2022 Oct 1;106(10):1935-1939
pubmed: 35404869
J Viral Hepat. 2020 Sep;27(9):941-947
pubmed: 32338810
J Infect Dis. 1987 May;155(5):931-5
pubmed: 3559292
J Hepatol. 2020 Nov;73(5):1046-1062
pubmed: 32634548
J Hepatol. 2010 Nov;53(5):834-40
pubmed: 20800919
Aliment Pharmacol Ther. 2021 Aug;54(4):462-469
pubmed: 34181772
Gut. 2000 Mar;46(3):420-6
pubmed: 10673308
Hepatology. 1991 Mar;13(3):413-6
pubmed: 1999312
Transpl Int. 2014 Oct;27(10):1022-8
pubmed: 24909714